American pharmaceutical companies are increasingly forming alliances with Chinese biotech firms, marking a major shift in global pharma dynamics. Nearly 30% of
Big Pharma is increasingly partnering with Chinese firms, with 30% of 2024 deals involving significant investments. China’s advanced drug development and rapid